MedPath

Short course normal saline infusion in contrast-enhanced computed tomography for contrast-associated acute kidney injury (CA-AKI) prevention in CKD G3b patients: An open-label randomized controlled trial and incidence of subclinical CA-AKI using kidney biomarkers

Phase 3
Conditions
There is a controversy to CA-AKI prevention in patients with elevated risk (CKD G3b) with short course normal saline infusion protocol with contrast-enhanced CT. Prevention is definitely useful for prevention of CA-AKI in CKD G4.
contrast associated acute kidney injury,
Registration Number
TCTR20221006001
Lead Sponsor
ational Research Council of Thailand (NRCT)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
nknown
Sex
All
Target Recruitment
192
Inclusion Criteria

CKD stage 3b that undergoing contrast-enhanced CT in Naresuan University hospital

Exclusion Criteria

Uncontrolled congestive heart failure
Cardiomyopathy with EF < 30%
Currently AKI from other causes
Septic shock or hemodynamically unstable
Pregnancy
Refuse inform consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Contrast associated acute kidney injury 48 h to 7 d serum creatinine,Receiver operating characteristic of contrast associated acute kidney injury 48 h to 7 d urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid binding protein
Secondary Outcome Measures
NameTimeMethod
subacute contrast associated acute kidney injury 48 h to 7 d urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid binding protein ,Receiver operating characteristic of contrast associated acute kidney injury 48 h to 7 d urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid binding protein
© Copyright 2025. All Rights Reserved by MedPath